Loading...
XNYSFNA
Market cap866mUSD
Jan 08, Last price  
10.35USD
1D
-3.54%
1Q
94.18%
IPO
-46.98%
Name

Paragon 28 Inc (Pre-Reincorporation)

Chart & Performance

D1W1MN
XNYS:FNA chart
P/E
P/S
4.00
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
216m
+19.30%
106,280,000110,981,000147,464,000181,383,000216,389,000
Net income
-48m
L-28.94%
3,117,0002,686,000-13,693,000-67,326,000-47,841,000
CFO
-64m
L+29.91%
12,298,0001,111,000-3,317,000-49,181,000-63,890,000

Profile

Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
IPO date
Oct 15, 2021
Employees
463
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
216,389
19.30%
181,383
23.00%
Cost of revenue
73,676
57,107
Unusual Expense (Income)
NOPBT
142,713
124,276
NOPBT Margin
65.95%
68.52%
Operating Taxes
213
(64)
Tax Rate
0.15%
NOPAT
142,500
124,340
Net income
(47,841)
-28.94%
(67,326)
391.68%
Dividends
Dividend yield
Proceeds from repurchase of equity
68,453
5,271
BB yield
-6.71%
-0.36%
Debt
Debt current
1,183
728
Long-term debt
111,895
43,556
Deferred revenue
342
Other long-term liabilities
635
1,813
Net debt
37,439
4,479
Cash flow
Cash from operating activities
(63,890)
(49,181)
CAPEX
(26,716)
(43,086)
Cash from investing activities
(26,987)
(60,693)
Cash from financing activities
128,653
39,487
FCF
75,848
94,823
Balance
Cash
75,639
38,468
Long term investments
1,337
Excess cash
64,820
30,736
Stockholders' equity
(114,671)
(67,046)
Invested Capital
405,320
252,855
ROIC
43.30%
70.86%
ROCE
49.06%
66.76%
EV
Common stock shares outstanding
82,087
76,766
Price
12.43
-34.96%
19.11
8.03%
Market cap
1,020,345
-30.45%
1,467,000
8.48%
EV
1,057,784
1,471,479
EBITDA
158,255
138,004
EV/EBITDA
6.68
10.66
Interest
5,165
4,129
Interest/NOPBT
3.62%
3.32%